FDA Cites ZLB's Rhophylac Promotions For Risk Info Omissions
This article was originally published in The Pink Sheet Daily
Executive Summary
ZLB is revising a Rhophylac website and has discontinued a sales brochure and patient Q&A cited in the warning letter issued by the Center for Biologics Evaluation & Research. The "main parts" of the promotions did not include sufficient risk information, FDA says.
You may also be interested in...
Rhophylac Unapproved Use Claims Targeted In CBER Untitled Letter
ZLB Behring is falsely promoting an unapproved indication for the immune globulin product in an American Hospital Formulary Service fact sheet, FDA says.
Rhophylac Unapproved Use Claims Targeted In CBER Untitled Letter
ZLB Behring is falsely promoting an unapproved indication for the immune globulin product in an American Hospital Formulary Service fact sheet, FDA says.
ZLB Rhophylac Clears FDA
ZLB Bioplasma will make its IGIV product Rhophylac available in the U.S. in March, the company said